As of 2025-01-15, the Intrinsic Value of Agios Pharmaceuticals Inc (AGIO) is
295.59 USD. This Agios valuation is based on the model Peter Lynch Fair Value.
With the current market price of 34.30 USD, the upside of Agios Pharmaceuticals Inc is
761.79%.
295.59 USD
Intrinsic Value
Agios Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(552.43) - (118.93) |
(193.32) |
-663.6% |
| DCF (Growth 10y) |
(118.46) - (497.27) |
(183.86) |
-636.0% |
| DCF (EBITDA 5y) |
(109.37) - (124.17) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(111.10) - (132.36) |
(1,234.50) |
-123450.0% |
| Fair Value |
295.59 - 295.59 |
295.59 |
761.79% |
| P/E |
229.62 - 326.81 |
274.31 |
699.7% |
| EV/EBITDA |
(100.61) - (108.64) |
(104.21) |
-403.8% |
| EPV |
(58.56) - (76.81) |
(67.69) |
-297.3% |
| DDM - Stable |
94.49 - 326.72 |
210.60 |
514.0% |
| DDM - Multi |
(43.09) - (118.02) |
(63.39) |
-284.8% |
Agios Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
1,956.13 |
| Beta |
2.55 |
| Outstanding shares (mil) |
57.03 |
| Enterprise Value (mil) |
1,702.40 |
| Market risk premium |
4.60% |
| Cost of Equity |
10.01% |
| Cost of Debt |
5.00% |
| WACC |
6.84% |